1. Targeting MAPK phosphorylation of Connexin43 provides neuroprotection in stroke.
- Author
-
Freitas-Andrade M, Wang N, Bechberger JF, De Bock M, Lampe PD, Leybaert L, and Naus CC
- Subjects
- Animals, Astrocytes metabolism, Connexin 43 antagonists & inhibitors, Connexin 43 genetics, Connexin 43 pharmacology, Disease Models, Animal, Gap Junctions metabolism, Gene Knock-In Techniques, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Microglia metabolism, Peptide Fragments pharmacology, Phosphorylation, Cerebral Infarction metabolism, Connexin 43 metabolism, Mitogen-Activated Protein Kinases metabolism, Neuroprotection drug effects, Neuroprotection genetics
- Abstract
Connexin43 (Cx43) function is influenced by kinases that phosphorylate specific serine sites located near its C-terminus. Stroke is a powerful inducer of kinase activity, but its effect on Cx43 is unknown. We investigated the impact of wild-type (WT) and knock-in Cx43 with serine to alanine mutations at the protein kinase C (PKC) site Cx43
S368A , the casein kinase 1 (CK1) sites Cx43S325A/328Y/330A , and the mitogen-activated protein kinase (MAPK) sites Cx43S255/262/279/282A (MK4) on a permanent middle cerebral artery occlusion (pMCAO) stroke model. We demonstrate that MK4 transgenic animals exhibit a significant decrease in infarct volume that was associated with improvement in behavioral performance. An increase in astrocyte reactivity with a concomitant decrease in microglial reactivity was observed in MK4 mice. In contrast to WT, MK4 astrocytes displayed reduced Cx43 hemichannel activity. Pharmacological blockade of Cx43 hemichannels with TAT-Gap19 also significantly decreased infarct volume in WT animals. This study provides novel molecular insights and charts new avenues for therapeutic intervention associated with Cx43 function., (© 2019 Freitas-Andrade et al.)- Published
- 2019
- Full Text
- View/download PDF